Summary statistics - qualitative results

EQA round: APLA1/23 - Antiphospholipid Antibodies   Deadline: 17.3.2023

Setup: all data

AV = assigned value	N_{tot} = total number of the results	N_{eva} = number of the results assessed
CVP = consensus of all participants	N_{rel} = relative number of the results	N_{suc} = number of successful results
>>> ... expected result		S_{rel} = relative success
> ... acceptable result		
± ... result not assessed		

Test / Sample / Group	AV		N_{tot}	N_{rel} [%]	Result	N_{eva}	N_{suc}	S_{rel} [%]
(465) anti-β2-glycoprotein 1 screening			13			13	13	100
Sample A			13			13	13	100
All results	CVP	>>>	13	100	Positive			
Sample B			13			13	13	100
All results	CVP	>>>	13	100	Positive			
(467) anti-β2-glycoprotein 1 IgG			61			61	61	100
Sample A			61			61	61	100
All results	CVP	>>>	61	100	Positive			
Sample B			61			61	61	100
All results	CVP	>>>	61	100	Positive			
(468) anti-β2-glycoprotein 1 IgM			60			60	59	98
Sample A			60			0		
All results		±	46	77	Negative			
		±	6	10	Inconclusive result (borderline)			
		±	8	13	Positive			
Sample B			60			60	59	98
All results	CVP	>>>	59	98	Negative			
			1	1,7	Positive			
(461) anti-cardiolipin screening			16			16	16	100
Sample A			16			16	16	100
All results	CVP	>>>	16	100	Positive			
Sample B			16			16	16	100
All results	CVP	>>>	16	100	Positive			
(463) anti-cardiolipin IgG			65			65	65	100
Sample A			65			0		
All results		±	12	18	Negative			
		±	1	1,5	Inconclusive result (borderline)			
		±	52	80	Positive			
Sample B			65			65	65	100
All results	CVP	>>>	65	100	Positive			
(464) anti-cardiolipin IgM			64			64	59	92
Sample A			64			64	59	92
All results	CVP	>>>	49	77	Negative			
		>	10	16	Inconclusive result (borderline)			
			5	7,8	Positive			
Sample B			64			64	64	100
All results	CVP	>>>	64	100	Negative			